Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 3481 |
| PDBID: | 7CU5 |
| Chains: | A_Q |
| Organism: | Homo sapiens |
| Method: | XRD |
| Resolution (Å): | 2.81 |
| Reference: | 10.15252/embr.202051444 |
| Antibody | |
| Antibody: | camrelizumab scFv |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Programmed cell death protein 1(PD-1) |
| Antigen mutation: | No |
| Durg Target: | Q15116 |
Sequence information
Antibody
Chain: A
Mutation: NULL
| >7CU5_A|Chain A, C[auth B]|camrelizumab-scFv|Homo sapiens (9606) MEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYMMSWVRQAPGKGLEWVATISGGGANTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLYYFDYWGQGTTVTVSSGGGGSDIQMTQSPSSLSASVGDRVTITCLASQTIGTWLTWYQQKPGKAPKLLIYTATSLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVYSIPWTFGGGTKVEIKR |
Antigen
Chain: Q
Mutation: NULL
| >7CU5_Q|Chain B[auth E], D[auth Q]|Programmed cell death protein 1|Homo sapiens (9606) RPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTER |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| A: THR28 SER31 TYR32 MET33 SER52 GLY53 GLY54 ALA56 ASN57 TYR59 LEU100 TYR101 Q: SER60 GLU61 SER62 VAL64 ASN66 LYS78 PHE82 PRO83 GLU84 GLN99 ILE126 LEU128 ALA129 PRO130 ALA132 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
